Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Ibrutinib

EU orphan designation number: EU/3/15/1541   
Active ingredient: Ibrutinib
Indication: Treatment of marginal zone lymphoma
Sponsor: Janssen-Cilag International NV
Turnhoutseweg 30, B-2340 Beerse, België

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
12/08/2015 Orphan designation EMA/OD/082/15 (2015)5777 of 10/08/2015